JPS62159B2 - - Google Patents
Info
- Publication number
- JPS62159B2 JPS62159B2 JP52028151A JP2815177A JPS62159B2 JP S62159 B2 JPS62159 B2 JP S62159B2 JP 52028151 A JP52028151 A JP 52028151A JP 2815177 A JP2815177 A JP 2815177A JP S62159 B2 JPS62159 B2 JP S62159B2
- Authority
- JP
- Japan
- Prior art keywords
- lys
- boc
- gly
- thr
- endorphin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- JMHFFDIMOUKDCZ-NTXHZHDSSA-N 61214-51-5 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 JMHFFDIMOUKDCZ-NTXHZHDSSA-N 0.000 description 34
- 102400000748 Beta-endorphin Human genes 0.000 description 29
- 101800005049 Beta-endorphin Proteins 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 150000001413 amino acids Chemical class 0.000 description 22
- 238000000034 method Methods 0.000 description 17
- 239000011347 resin Substances 0.000 description 14
- 229920005989 resin Polymers 0.000 description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- -1 amino-protected glutamine Chemical class 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 229960000583 acetic acid Drugs 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 150000008064 anhydrides Chemical class 0.000 description 8
- 238000005406 washing Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 5
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 108010042362 beta-Lipotropin Proteins 0.000 description 5
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 241000282836 Camelus dromedarius Species 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 108090000787 Subtilisin Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000003635 pituitary gland Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003402 opiate agonist Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- DMBKPDOAQVGTST-GFCCVEGCSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylmethoxypropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)COCC1=CC=CC=C1 DMBKPDOAQVGTST-GFCCVEGCSA-N 0.000 description 2
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 2
- QJCNLJWUIOIMMF-YUMQZZPRSA-N (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C QJCNLJWUIOIMMF-YUMQZZPRSA-N 0.000 description 2
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 2
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 2
- FYYSQDHBALBGHX-YFKPBYRVSA-N N(alpha)-t-butoxycarbonyl-L-asparagine Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(N)=O FYYSQDHBALBGHX-YFKPBYRVSA-N 0.000 description 2
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000004816 paper chromatography Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013014 purified material Substances 0.000 description 2
- GAPYKZAARZMMGP-UHFFFAOYSA-N pyridin-1-ium;acetate Chemical compound CC(O)=O.C1=CC=NC=C1 GAPYKZAARZMMGP-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical group C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HQALISCIMNBRAE-XJTHNYJFSA-N 59887-17-1 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 HQALISCIMNBRAE-XJTHNYJFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- CIHWJRSPVJBHGT-UHFFFAOYSA-N benzhydrylazanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(N)C1=CC=CC=C1 CIHWJRSPVJBHGT-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920006026 co-polymeric resin Polymers 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000012351 deprotecting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000540 fraction c Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/675—Beta-endorphins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/667,747 US4038222A (en) | 1976-03-17 | 1976-03-17 | Untriakontapeptide with opiate activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS52113958A JPS52113958A (en) | 1977-09-24 |
| JPS62159B2 true JPS62159B2 (pt-PT) | 1987-01-06 |
Family
ID=24679466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2815177A Granted JPS52113958A (en) | 1976-03-17 | 1977-03-16 | Hetriaconpeptide |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US4038222A (pt-PT) |
| JP (1) | JPS52113958A (pt-PT) |
| AR (2) | AR222778A1 (pt-PT) |
| AT (1) | AT355238B (pt-PT) |
| AU (1) | AU514499B2 (pt-PT) |
| BE (1) | BE852510A (pt-PT) |
| CA (1) | CA1092602A (pt-PT) |
| CH (1) | CH625785A5 (pt-PT) |
| DE (1) | DE2711487C2 (pt-PT) |
| DK (1) | DK149203C (pt-PT) |
| ES (2) | ES456901A1 (pt-PT) |
| FI (1) | FI63391C (pt-PT) |
| FR (1) | FR2348912A1 (pt-PT) |
| GB (1) | GB1563654A (pt-PT) |
| GR (1) | GR63092B (pt-PT) |
| IE (1) | IE44226B1 (pt-PT) |
| IL (1) | IL51660A (pt-PT) |
| LU (1) | LU76963A1 (pt-PT) |
| MC (1) | MC1137A1 (pt-PT) |
| NL (1) | NL7702849A (pt-PT) |
| NO (1) | NO147105C (pt-PT) |
| NZ (1) | NZ183605A (pt-PT) |
| PH (1) | PH13864A (pt-PT) |
| PT (1) | PT66311B (pt-PT) |
| SE (1) | SE436354B (pt-PT) |
| ZA (1) | ZA771593B (pt-PT) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4320117A (en) * | 1976-06-21 | 1982-03-16 | Imperial Chemical Industries Limited | Polypeptide |
| US4123523A (en) * | 1976-06-21 | 1978-10-31 | Imperial Chemical Industries Limited | Analgesic and sedative polypeptides |
| US4371463A (en) * | 1977-02-17 | 1983-02-01 | The United States Of America As Represented By The Department Of Health And Human Services | Enzyme-resistant opiate pentapeptides |
| US4081434A (en) * | 1977-03-11 | 1978-03-28 | Hoffmann-La Roche Inc. | Novel analogs of β-endorphin |
| US4098781A (en) * | 1977-03-11 | 1978-07-04 | American Home Products Corporation | Polypeptides with morphine-like activity |
| US4317770A (en) * | 1977-03-11 | 1982-03-02 | Hoffmann-La Roche Inc. | D-amino acid analogs of beta-endorphin |
| US4127521A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel octacosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said octacosapeptides |
| US4127523A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel undecapeptides, intermediates therefor, and compositions and methods employing said undecapeptides |
| US4127532A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel heptapeptides, intermediates therefor, and compositions and methods employing said heptapeptides |
| US4127519A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Octadecapeptides, intermediates therefor, and compositions and methods employing said octadecapeptides |
| US4127524A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel dodecapeptides, intermediates therefor, and compositions and methods employing said dodecapeptides |
| US4127538A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel pentacosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said pentacosapeptides |
| US4127525A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tridecapeptides, intermediates therefor, and compositions and methods employing said tridecapeptides |
| US4127517A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel docosapeptides, intermediates therefore and pharmaceutical compositions and methods employing said docosapeptides |
| US4127530A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel heneicosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said heneicosapeptides |
| US4312857A (en) * | 1977-06-16 | 1982-01-26 | The United States Of America As Represented By The Veterans Administration | Novel derivatives of beta-endorphin, intermediates therefor and compositions and methods employing said derivatives |
| US4127539A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel hexacosapeptides, intermediates therefore and pharmaceutical compositions and methods employing said hexacosapeptides |
| US4127527A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel pentadecapeptides, intermediates therefor, and compositions and methods employing said pentadecapeptides |
| US4127540A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel derivatives of δ-endorphins, intermediates therefor, and compositions and methods employing said derivatives |
| US4127522A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel triacontapeptides, intermediates therefor and pharmaceutical compositions and methods employing said triacontapeptides |
| ZA783287B (en) * | 1977-06-16 | 1980-01-30 | D Coy | Novel polypeptides |
| US4127526A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tetradecapeptides, intermediates therefor, and compositions and methods employing said tetradecapeptides |
| US4127537A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tetracosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said tetracosapeptides |
| US4127535A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel dipeptides, intermediates therefor, and compositions and methods employing said dipeptides |
| US4127520A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel nonadecapeptides, intermediates therefor, and compositions and methods employing said nonadecapeptides |
| US4127529A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel eicosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said eicosapeptides |
| US4127528A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel derivatives of alpha-endorphin, intermediates therefor and compositions and methods employing said derivatives |
| US4127541A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel decapeptides, intermediates therefor, and compositions and methods employing said decapeptides |
| US4127531A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel hexapeptides, intermediates therefor, and compositions and methods employing said hexapeptides |
| US4127536A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tricosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said tricosapeptides |
| US4127534A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tripeptides, intermediates therefor and pharmaceutical compositions and methods employing said tripeptides |
| US4127518A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel derivatives of gamma-endorphins, intermediates therefor, and compositions and methods employing said derivatives |
| US4127533A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel octapeptides, intermediates therefor, and compositions and methods employing said octapeptides |
| US4139504A (en) * | 1977-06-16 | 1979-02-13 | Coy David Howard | Novel nonapeptides, intermediates therefor, and compositions and methods employing said nonapeptides |
| US4105652A (en) * | 1977-08-05 | 1978-08-08 | Hoffmann-La Roche Inc. | Synthesis of human β-endorphin |
| US4232008A (en) * | 1978-11-17 | 1980-11-04 | Ortho Pharmaceutical Corporation | Tetrapeptides and methods |
| US4116950A (en) * | 1978-01-16 | 1978-09-26 | Hoffmann-La Roche Inc. | Analogs of human β-endorphin |
| US4330465A (en) * | 1978-03-02 | 1982-05-18 | Hoffmann-La Roche Inc. | Novel β-endorphin analogs |
| US4219468A (en) * | 1978-11-13 | 1980-08-26 | Hoffmann-La Roche Inc. | Tritiated β-endorphin |
| US4396606A (en) | 1979-11-05 | 1983-08-02 | Addiction Research Foundation | Novel polypeptide analgesics |
| US4250087A (en) * | 1979-12-10 | 1981-02-10 | Hoffmann-La Roche Inc. | Carboxyl terminus analogs of β-endorphin |
| JPS56108750A (en) * | 1980-02-01 | 1981-08-28 | Takeda Chem Ind Ltd | Polypeptide and its preparation |
| US4438104A (en) | 1980-01-03 | 1984-03-20 | Endorphin, Inc. | Endorphins having placental or pancreatic origin |
| US4316895A (en) * | 1980-01-03 | 1982-02-23 | Kimball Charles D | Endorphins having placental or pancreatic origin |
| US4350764A (en) * | 1980-03-10 | 1982-09-21 | The Regents Of The University Of California | Microbiological synthesis of beta endorphin |
| US4313937A (en) * | 1980-08-12 | 1982-02-02 | Tsutomu Oyama | Method for producing long-lasting analgesic effects of β-endorphin |
| GB2111505B (en) * | 1981-06-16 | 1984-09-26 | Charles D Kimball | Endorphins having placental or pancreatic origin |
| FR2857873B1 (fr) * | 2003-07-21 | 2006-02-24 | Courtage Et De Diffusion Codif | Procede et produit cosmetique destines a limiter la croissance des tissus adipeux |
-
1976
- 1976-03-17 US US05/667,747 patent/US4038222A/en not_active Expired - Lifetime
-
1977
- 1977-02-16 CH CH193477A patent/CH625785A5/de not_active IP Right Cessation
- 1977-03-06 AU AU23298/77A patent/AU514499B2/en not_active Expired
- 1977-03-09 MC MC771235A patent/MC1137A1/xx unknown
- 1977-03-15 CA CA274,024A patent/CA1092602A/en not_active Expired
- 1977-03-15 FR FR7707621A patent/FR2348912A1/fr active Granted
- 1977-03-15 NZ NZ183605A patent/NZ183605A/xx unknown
- 1977-03-15 PH PH19558A patent/PH13864A/en unknown
- 1977-03-15 IL IL51660A patent/IL51660A/xx unknown
- 1977-03-16 AR AR266874A patent/AR222778A1/es active
- 1977-03-16 GB GB11109/77A patent/GB1563654A/en not_active Expired
- 1977-03-16 NO NO770941A patent/NO147105C/no unknown
- 1977-03-16 PT PT66311A patent/PT66311B/pt unknown
- 1977-03-16 BE BE175818A patent/BE852510A/xx not_active IP Right Cessation
- 1977-03-16 ES ES456901A patent/ES456901A1/es not_active Expired
- 1977-03-16 JP JP2815177A patent/JPS52113958A/ja active Granted
- 1977-03-16 SE SE7703004A patent/SE436354B/xx not_active IP Right Cessation
- 1977-03-16 IE IE571/77A patent/IE44226B1/en unknown
- 1977-03-16 DE DE2711487A patent/DE2711487C2/de not_active Expired
- 1977-03-16 FI FI770835A patent/FI63391C/fi not_active IP Right Cessation
- 1977-03-16 DK DK116177A patent/DK149203C/da not_active IP Right Cessation
- 1977-03-16 LU LU76963A patent/LU76963A1/xx unknown
- 1977-03-16 ZA ZA00771593A patent/ZA771593B/xx unknown
- 1977-03-16 AT AT178877A patent/AT355238B/de not_active IP Right Cessation
- 1977-03-16 NL NL7702849A patent/NL7702849A/xx not_active Application Discontinuation
- 1977-03-17 GR GR53010A patent/GR63092B/el unknown
- 1977-08-08 US US05/822,772 patent/USRE29842E/en not_active Expired - Lifetime
- 1977-11-25 AR AR270126A patent/AR222007A1/es active
-
1978
- 1978-03-01 ES ES467453A patent/ES467453A1/es not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS62159B2 (pt-PT) | ||
| Gregory et al. | The primary structure of human urogastrone | |
| JP2679786B2 (ja) | 非ペプチド結合を有するペプチド合成方法 | |
| US4629723A (en) | Potent thymopentin analogs | |
| US4098778A (en) | β-Endorphin analog | |
| Channabasavaiah et al. | New analogs of luliberin which inhibit ovulation in the rat | |
| Li et al. | β‐endorphin: isolation, amino acid sequence and synthesis of the hormone from horse pituitary glands | |
| EP0315687B1 (en) | (n-alpha-acyl, 8-glycine, des-19-leucine)-calcitonin | |
| JPH051798B2 (pt-PT) | ||
| Stetler-Stevenson et al. | An approach to the elucidation of metabolic breakdown products of the luteinizing hormone-releasing hormone | |
| AU703400B2 (en) | Antagonists of LHRH | |
| US4264492A (en) | Enkephalin-like compounds in bovine adrenal medulla | |
| Boissonnas et al. | Chemistry of the neurohypophysial hormones | |
| US4820804A (en) | Analogs of [1,7-di-alanine, des-19-leucine]calcitonin | |
| CA1108122A (en) | Protected coupled hentriakontapeptide intermediates | |
| EP0380554B1 (en) | Vasoactive peptides | |
| JPH09157294A (ja) | 副甲状腺ホルモン誘導体 | |
| KR810000736B1 (ko) | 헨트리아콘타 펩타이드 유도체의 제조방법 | |
| Li et al. | β-endorphin: Replacement of glutamic acid in position 8 by glutamine increases analgesic potency and opiate receptor-binding activity | |
| BLAKE et al. | β‐ENDORPHIN: SYNTHESIS AND RADIOLIGAND BINDING ACTIVITY OF ANALOGS CONTAINING CYSTINE BRIDGES | |
| US4639509A (en) | [16,19-Di-alanine] calcitonin | |
| EP0297159A1 (en) | [N-Acyl, 1,7-Di-Aline] calcitonins, method for their preparation, pharmaceutical compositions and use | |
| EP0287997A2 (en) | Des-19-leucine, 20-glutamine, 21-threonine-calcitonin | |
| US4824936A (en) | (19-Alanine) calcitonin | |
| US4422968A (en) | β-Endorphin analogs |